ArticleFrontiers in oncology2022

Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma.

Dawei Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.